Subtotal $0.00
Shop Now
There is no Ozempic generic on sale in the United States as of October 2026. The FDA granted one tentative approval for a generic semaglutide injection in April 2026, which means the product met the scientific standards but cannot be marketed until patents and exclusivity are resolved. The main semaglutide patent listed in the FDA’s Orange Book runs to December 2031, so a U.S. launch before the early 2030s would need a court win or a settlement. Other countries are ahead: Canada approved generic semaglutide in 2026, and Indian companies launched versions after the patent there expired in March 2026. Compounded semaglutide is not a generic and is not FDA-approved.
Peptide Labs does not sell Ozempic, Wegovy, semaglutide or any prescription drug. This article summarizes FDA, Orange Book and Health Canada records. For what makes a product an approved drug, see our explainer on FDA-approved semaglutide and tirzepatide.
Key Takeaways
- No generic Ozempic or Wegovy can be sold in the U.S. in 2026.
- Apotex received a tentative FDA approval for generic semaglutide in April 2026.
- The core semaglutide patent in the Orange Book expires in December 2031.
- Canada approved generic semaglutide for diabetes in April 2026 and for weight management in June 2026.
- Compounded semaglutide is not a generic copy and has not been FDA-reviewed.
- The FDA has warned about counterfeit Ozempic pens found in the U.S. supply chain.
Is there an Ozempic generic in the U.S.?
Not yet. A generic drug is approved through an abbreviated new drug application (ANDA), which must show the copy has the same active ingredient, strength, form and route as the brand and works the same way in the body. In the FDA’s Drugs@FDA database, the only semaglutide ANDA, from Apotex, shows a tentative approval dated April 7, 2026, with no marketing status. Tentative approval is a common step for blockbuster drugs: the FDA has finished its scientific review, but legal barriers still stop the product from reaching pharmacies.
The same applies to Wegovy and to the Rybelsus and Ozempic tablets, which contain the same molecule. No generic semaglutide in any form, and no generic tirzepatide, can be sold in the U.S. today.
Semaglutide patent expiration: what the Orange Book shows
The FDA’s Orange Book lists the patents and exclusivity periods a brand company says protect its drug. For Ozempic injection, the entries checked on October 1, 2026 show:
| Orange Book entry | What it covers | Expiration |
|---|---|---|
| Patent 8,129,343 | Semaglutide itself (drug substance and product) | December 5, 2031 |
| Patent 8,536,122 | Drug substance and product | Expired March 20, 2026 |
| Patent 10,335,462 | A listed method of use | June 21, 2033 |
| New-indication exclusivity | Protects a newer approved use | January 28, 2028 |
| Most pen-device patents | Delisted from the Orange Book | No longer listed |
These dates set the outer limits, not the actual launch date. Generic companies can challenge patents in court, and brand companies often settle such cases with an agreed entry date that is not made public. A new-indication exclusivity usually blocks only that use on a generic label rather than the whole product. Because of these moving parts, nobody can give a confirmed answer to when Ozempic will be generic in the U.S.; the Orange Book points to the early 2030s unless a court or settlement changes that. A patent law firm’s 2026 analysis likewise expected no generics in the U.S., Europe or Japan in 2026 and loss of exclusivity in Europe around 2031.
Generic semaglutide outside the U.S.
Patent terms differ by country, and generic semaglutide has already arrived in some markets:
- Canada: a core semaglutide patent was allowed to lapse. On April 28, 2026, Health Canada approved Dr. Reddy’s generic semaglutide referencing Ozempic for adults with type 2 diabetes, the first approval of its kind in a G7 country. On June 29, 2026 it approved Apotex’s Sevmia, a generic referencing Wegovy for weight management in people 12 and older, with more submissions under review.
- India: the semaglutide product patent expired on March 20, 2026, and Indian drugmakers launched generic versions; a Delhi High Court ruling that day declined to block one of them.
- China and Brazil: core patents also expire in 2026, according to patent attorneys. Local approval decisions are separate and vary.
A product approved in Canada or India is not FDA-approved for U.S. use. The FDA warns that medicines from unverified online sellers may be fake or contaminated, and advises filling prescriptions only at state-licensed pharmacies.
Compounded copies are not generic semaglutide
People often call compounded semaglutide “generic Ozempic”, but the two are legally and practically different. A generic is reviewed by the FDA for quality and sameness before approval. A compounded drug is mixed by a pharmacy for an individual prescription and is not FDA-approved or reviewed for safety, effectiveness or quality. The FDA also says some compounders used salt forms, such as semaglutide sodium or acetate, which are different active ingredients from the semaglutide in Ozempic.
Broad compounding of semaglutide was tied to the drug shortage, which the FDA declared resolved on February 21, 2025; its temporary flexibility for compounders ended later that spring. Our compounded semaglutide and tirzepatide guide explains what is still allowed. Products sold online as “research” semaglutide, labeled not for human consumption, are neither generic nor compounded drugs, and the FDA calls their sale for human use illegal.
Counterfeit Ozempic warnings
Demand and the lack of a U.S. generic have attracted counterfeiters. Since December 2023 the FDA has warned about counterfeit Ozempic pens found in the legitimate U.S. drug supply chain, some with counterfeit needles whose sterility could not be confirmed. The agency told pharmacies to obtain Ozempic only through Novo Nordisk’s authorized distributors and lists the lot numbers involved on its website. If a pen, label or carton looks different from usual, ask the pharmacist before using it.
Options while there is no generic
For now, the generic GLP-1 drugs in the U.S. are older ones. Generic liraglutide is approved for type 2 diabetes (referencing Victoza) and for weight management (referencing Saxenda), and generic exenatide is approved for type 2 diabetes. These are daily or twice-daily medicines with their own trial results; our liraglutide vs semaglutide comparison sets out the differences, and our GLP-1 drugs list shows every approved brand. Whether any of them suits a particular person is a prescriber’s call.
Our Wegovy and Ozempic comparison explains why the same molecule has two brand names, and our overview of Ozempic alternatives looks at other approved medicines and what supplements can and cannot do.
Frequently Asked Questions
Is there a generic Ozempic?
Not in the U.S. as of October 2026. One generic semaglutide has FDA tentative approval but cannot be sold until patent and exclusivity issues are resolved. Canada and India have generic versions.
When will Ozempic be generic?
No U.S. date is confirmed. The core patent listed in the Orange Book expires in December 2031, so generics before then would depend on court rulings or settlements.
When does the semaglutide patent expire?
In the U.S., the main Orange Book patent for Ozempic runs to December 5, 2031. Core patents expired or lapsed in India, Canada and several other countries in 2026.
Is compounded semaglutide the same as generic semaglutide?
No. Generics are FDA-reviewed for sameness and quality. Compounded semaglutide is not FDA-approved, and some compounders used salt forms that differ from the drug in Ozempic.
Is there a generic Wegovy?
Not in the U.S. Health Canada approved a generic referencing Wegovy in June 2026, but that product is not FDA-approved.
Are there any generic GLP-1 drugs in the U.S.?
Yes. Generic liraglutide for diabetes and for weight management, and generic exenatide for diabetes, are FDA-approved.
Peptide Labs does not sell GLP-1 medicines or any prescription drug. This article is general information, not medical advice. Read the Medication Guide that comes with a prescription, and ask a pharmacist or prescriber how this information applies to you.
Last reviewed October 2026.
Related guides: Compounded Semaglutide and Tirzepatide: What Is Allowed Now, Ozempic Alternatives: FDA-Approved Options, OTC Facts and What to Avoid, Wegovy vs Ozempic: Same Semaglutide, Different Labels.